Using Multiplex Amplicon PCR Technology to Efficiently and Timely Generate Rift Valley Fever Virus Sequence Data for Genomic Surveillance

Viruses. 2023 Feb 9;15(2):477. doi: 10.3390/v15020477.

Abstract

Rift Valley fever (RVF) is a febrile vector-borne disease endemic in Africa and continues to spread in new territories. It is a climate-sensitive disease mostly triggered by abnormal rainfall patterns. The disease is associated with high mortality and morbidity in both humans and livestock. RVF is caused by the Rift Valley fever virus (RVFV) of the genus Phlebovirus in the family Phenuiviridae. It is a tripartite RNA virus with three genomic segments: small (S), medium (M) and large (L). Pathogen genomic sequencing is becoming a routine procedure and a powerful tool for understanding the evolutionary dynamics of infectious organisms, including viruses. Inspired by the utility of amplicon-based sequencing demonstrated in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and Ebola, Zika and West Nile viruses, we report an RVFV sample preparation based on amplicon multiplex polymerase chain reaction (amPCR) for template enrichment and reduction of background host contamination. The technology can be implemented rapidly to characterize and genotype RVFV during outbreaks in a near-real-time manner. To achieve this, we designed 74 multiplex primer sets covering the entire RVFV genome to specifically amplify the nucleic acid of RVFV in clinical samples from an animal tissue. Using this approach, we demonstrate achieving complete RVFV genome coverage even from samples containing a relatively low viral load. We report the first primer scheme approach of generating multiplex primer sets for a tripartite virus which can be replicated for other segmented viruses.

Keywords: Rift Valley fever; amplicon; culture; enrichment; genome; multiplex PCR.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Animals
  • COVID-19 Testing
  • COVID-19*
  • Genomics
  • Humans
  • Multiplex Polymerase Chain Reaction
  • Rift Valley Fever*
  • Rift Valley fever virus* / genetics
  • SARS-CoV-2 / genetics
  • Zika Virus Infection*
  • Zika Virus*

Grants and funding

The research reported in this publication was supported through a research-for-development project, Boosting Uganda’s Investments in Livestock Development (BUILD), led by the International Livestock Research Institute (ILRI) and funded by the German government through the Federal Ministry of Economic Cooperation and Development (BMZ), Grant No. BMZ001201. Additional funding was received from the Rockefeller Foundation and the Africa CDC through a sub-grant award to S.O.O., the CGIAR Research Programs on Livestock and Agriculture for Nutrition Health and the Department of Defense’s Defense Threat Reduction Agency, Grant No. HDTRA11910031, supporting the project ‘Co-infection with Rift Valley fever virus, Brucella spp. and Coxiella burnetii in humans and animals in Kenya: Disease burden and ecological factors’. We also acknowledge the CGIAR Fund Donors (https://www.cgiar.org/funders (accessed on 7 November 2022)).